While we have recently curtailed our research on Herpes Simplex Virus (HSV), we continue to work on viral vectors that can effectively deliver CRISPR/Cas to virus-infected cells in vivo as a potential approach to a cure for several chronic viral infections. While we are currently focused on HPV16 and HIV-1 as potential targets, improved viral delivery vectors for Cas9 clearly would be potentially applicable in other viral diseases, including those caused by HSV.